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OBJECTIVES: Through advances in molecular biology, new treatment options for
patients with metastatic renal cell carcinoma (RCC) have become available. Al-
though the efficacy of these new treatments has been demonstrated in large ran-
domised controlled trials, their effectiveness in daily practice is currently un-
known. The aim of this study was to evaluate the use of new treatment options for
patients with metastatic RCC in Dutch daily practice. METHODS: A population-
based registry has been created to collect data about patients diagnosed with met-
astatic RCC in 2008, 2009 and 2010. This registry contains data on patient and
tumour characteristics, treatment details (e.g., dosing) and response to treatment.
All patients living within the regions of four Dutch Cancer Registries are being
included in this study. Together these registries cover 55% of The Netherlands.
RESULTS: Forty-three patients, all diagnosed with metastatic RCC in 2008, are cur-
rently included in our registry. Of these, 47% received systemic therapy (mostly
sunitinib), while all others received surgery or palliative care. Patients treated with
sunitinib in Dutch daily practice were five years older and had a worse ECOG
performance status than patients treated with sunitinib in the pivotal phase 3 trial.
While the mean daily dose seen in Dutch daily practice in the first cycle was
comparable to the recommended dose (50 mg), the mean daily dose in the second
cycle was lower, i.e. 44 mg. CONCLUSIONS: The number of Dutch patients with
metastatic RCC treated with systemic therapy will increase because of new treat-
ments available since 2008. This study suggests that patients treated with systemic
therapy in daily practice have a different profile and receive different dose sched-
ules than patients treated in the pivotal trial. Consequently, the effectiveness of the
new treatment options in Dutch daily practice may also differ from what was seen
in the trial.
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OBJECTIVES: To examine trends in chemotherapy and biologic regimens used in
1st, 2nd and 3rd line treatment of patients with colorectal cancer (CRC) in the US.
METHODS:Adult patients newly diagnosed with CRC from January 1, 2005- Decem-
ber 31, 2009 were selected from the Thomson Reuters MarketScan® Commercial
and Medicare Supplemental insurance claims databases. Patients were required to
have at least one cycle of chemotherapy and were followed from the administra-
tion of the first dose until the end of continuous insurance coverage or December
31, 2009, whichever came first. Evolution of first-, second-, and third-line treat-
ments from 2005 to 2009 is described. RESULTS: A total of 13,670 patients met the
study criteria. All had data on first-line treatment, 4,442 on second line, and 1,610
on third line. The most common first-line regimens were 5-fluorouracil (5-FU), 5-FU
and leucovorin (5-FU/LV), 5-FU/LV plus oxaliplatin (FOLFOX), and capecitabine.
Between 2005-2009, first-line use of FOLFOX increased from 25% to 35%, while use
of 5-FU/LV decreased from 18% to 7%. Second-line regimens were more diverse
with the most prevalent regimens being FOLFOX alone, FOLFOX plus bevacizumab,
5-FU/LV, and 5-FU/LV plus irinotecan (FOLFIRI) plus bevacizumab. Use of 5-FU/LV
as second-line treatment decreased from 12% in 2005 to 4% in 2009 as patients
received more diverse treatments. Between 2005-2009, third-line standard of care
moved toward biologic-containing regimens including FOLFIRI plus bevacizumab
and irinotecan plus cetuximab. Use of biologic regimens increased with each ther-
apy line and over time with 73% of third-line regimens in 2009 containing at least
one biologic compared with 57% in 2005. CONCLUSIONS:Over time the standard of
care chemotherapy for first-line CRC therapy has shifted away from 5-FU/LV to
FOLFOX, second line from 5FU/LV to more diverse treatments, and third line ther-
apy toward biologic containing regimens. Use of biologic regimens increased with
subsequent therapy line and over time.
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OBJECTIVES: To examine patient and disease characteristics and treatment pat-
terns among patients with chronic myeloid leukemia (CML) in multiple countries.
METHODS: Oncologists and hematologists in the United States (US), UK (UK), Ger-
many, and Japan abstracted medical charts of adult patients with CML between
January 1, 2005 and December 31, 2009. Patients were in chronic phase at diagnosis,
either Ph or BCR-ABL positive, had received first line treatment with imatinib, and
had not participated in a randomized clinical trial for CML. A subset of patients
received 2nd-line therapy with nilotinib or dasatinib. RESULTS: A total of 214 phy-
sicians provided data on 1,063 patients (range 220 – 300 per country). Patients were
55 years of age on average and 60% were male. Nearly 67% of patients did not have
any comorbidity, although when present, diabetes was most common in all coun-
tries (5% in Japan to 18% in Germany). Patients initiated imatinib within 3 months
after diagnosis, and received therapy for 22 months on average (19 months [US] to
25 months [Japan]), at a median daily dose of 400mg in all countries. Approximately
13% of patients (8% in Japan to 16% in UK) had a dose escalation to a median dose
of 800mg. 29% of patients discontinued imatinib, primarily due to resistance to
therapy or disease progression. 2nd-line treatment patterns were studied among
261 patients (148 dasatinib, 113 nilotinib). Patients in the US and Germany had
more nilotinib use (54%) while only 17% of UK patients used nilotinib. Patients
initiated 2nd-line therapy 25 months after initial diagnosis, and received treatment
for 11 months (dasatinib) or 7 months (nilotinib). More patients initiating dasatinib
had advanced disease (25% accelerated, 4% blast phase) compared to nilotinib (25%
accelerated, 1% blast phase). CONCLUSIONS: Patient characteristics and treat-
ment patterns in CML vary by country.
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OBJECTIVES: This retrospective study aimed at collecting real-life data regarding
chemotherapeutical treatments administered for metastatic prostate cancer in
Belgium. METHODS: From the Hospital Disease Database (year 2008), which in-
cludes data on full hospitalizations and day clinic for 34.3% of Belgian hospital
beds, stays of patients with metastatic prostate cancer were selected based on the
combination of ICD-9-CM codes for prostate cancer (185) and metastasis (196-197-
198-199). Chemotherapy sessions were identified using the ICD-9-CM code V58.1.
Identification of chemotherapeutical regimens was based on drug names. In addi-
tion, grade III/IV haematologic toxicities were identified using ICD-9-CM codes.
RESULTS: Among the 1171 patients identified with metastatic prostate cancer in
2008, 387 ( 33%) were administered chemotherapy. The total number of chemo-
therapies administered was 521; 272 patients (70.3%) received only one regimen, 97
(25.1%) received two different regimens, 17 (4.4%) and 1 (0.3%) patient received
respectively three and 4 regimens during the year. For 38.7% of chemotherapies,
the regimen could not be identified. These may represent chemotherapies admin-
istered in clinical trial or compassionate use setting. 201 (51.9%) of chemotherapy
patients received at least one docetaxel-containing regimen. 194 (50.1%) received
docetaxel monotherapy and 10 (2.6%) received docetaxel in combination with an-
other chemotherapeutical agent. The second most commonly identified regimen
was mitoxantrone monotherapy, administered to 39 patients (10.1%): 22 of them
had received prior docetaxel within the same calendar year. The average number of
cycles was 5.83 for docetaxel and 3.27 for mitoxantrone. Other chemotherapy reg-
imens included carboplatin-, fluorouracil- and cisplatin-containing regimens (re-
spectively 4.9%, 3.9% and 2.6% of patients). Among the patients treated with che-
motherapy, 21 (5.4%) developed (febrile) neutropenia, 90 (23.3%) had anemia and 37
(9.6%) had thrombocytopenia.CONCLUSIONS:This study shows that real-life prac-
tice is in line with the European guidelines, recommending docetaxel as first option
for chemotherapy in metastatic prostate cancer.
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OBJECTIVES: To describe treatment patterns in patients with metastatic mela-
noma (MM) in the US. METHODS: Using a large US medical claims database, pa-
tients were identified between 2005 and 2010 using 2melanoma diagnoses (ICD-
9-CM: 172.xx, V10.82) and 2 diagnoses for metastasis (ICD-9-CM: 197.xx, 198.xx).
The index date was the first date of metastasis diagnosis. Patients who had other
primary malignant tumors prior to the melanoma diagnosis, were younger than 18
years old at the index, or had a pre-index period of less than 6 months, were
excluded from the analysis. Patients were followed from the index date to death,
disenrollment, or end of the study period (June 30, 2010), whichever occurred first.
Drug, surgery, and radiation therapy were examined descriptively. The trend of
treatment patterns over the years was also examined. RESULTS:A total of 2546 MM
patients who met the study inclusion and exclusion criteria were included in the
analyses. Mean ( standard deviation) age was 60.6 ( 14.0) years old and 36.5%
were female. Mean length of follow-up observation period was 322 days. The most
common site of metastasis at the index date was lung (21.2%), brain and spinal cord
(18.7%), distant area of the skin (11.4%), bone (11.2%), and liver (10.0%). Overall,
56.8% of patients received cancer-related surgery, 38.7% received drug treatment,
and 44.7% received radiation therapy after MM diagnosis. Among patients who
received drug treatment, 48.7% received temozolomide, 22.3% paclitaxel, 19.4%
carboplatin, 17.6% interleukin-2 (IL-2), 17.2% dacarbazine (DTIC), 14.4% interferon
alfa-2b (IFN), 9.9% cisplatin, 6.3% vinblastine, 4.7% granulocyte-macrophage colo-
ny-stimulating factor (GM-CSF), 4.5% docetaxel, 2.0% carmustine, and 0.2% bacillus
calmette-guerin (BCG). CONCLUSIONS: Approximately 39% of MM patients were
treated with chemotherapy or immunotherapy and this pattern remained similar
during the last decade, which suggests an unmet need for patients with advanced
melanoma.
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OBJECTIVES: The survey was initiated to gain insights into the implementation of
decision-making tools in national guidelines in treatment patterns of mCRC in
daily practice. The tools define treatment intensity for subgroups of patients by
clinical characteristics and anticipated treatment aims. METHODS: Physicians in
representative sample of centres (69) reported all pts. with treatment decision in
October-December 2009. The database contains 1019 pts. with retrospective record
of treatment history. Treatment decisions were analysed in 3 predefined subgroups
according to a model based on the German guidelines. Statistics were performed in
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